| Literature DB >> 31434474 |
William T Barker1, Ansley M Nemeth1, Sara M Brackett1, Akash K Basak1, Courtney E Chandler2, Leigh A Jania3, William J Zuercher4, Roberta J Melander1, Beverly H Koller3, Robert K Ernst2, Christian Melander1.
Abstract
Kinase inhibitors comprise a diverse cohort of chemical scaffolds that are active in multiple biological systems. Currently, thousands of eukaryotic kinase inhibitors are commercially available, have well-characterized targets, and often carry pharmaceutically favorable toxicity profiles. Recently, our group disclosed that derivatives of the natural product meridianin D, a known inhibitor of eukaryotic kinases, modulated behaviors of both Gram-positive and Gram-negative bacteria. Herein, we expand our exploration of kinase inhibitors in Gram-negative bacilli utilizing three commercially available kinase inhibitor libraries and, ultimately, identify two chemical structures that potentiate colistin (polymyxin E) in multiple strains. We report IMD-0354, an inhibitor of IKK-β, as a markedly effective adjuvant in colistin-resistant bacteria and also describe AR-12 (OSU-03012), an inhibitor of pyruvate dehydrogenase kinase-1 (PDK-1), as a potentiator in colistin-sensitive strains. This report comprises the first description of the novel cross-reactivity of these molecules.Entities:
Keywords: antibiotic adjuvants; colistin; lipid A; multidrug-resistant Gram-negative bacteria
Mesh:
Substances:
Year: 2019 PMID: 31434474 PMCID: PMC6944324 DOI: 10.1021/acsinfecdis.9b00212
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084